Explore ›
Finding
Finding
improvement
Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.
| Effect size | b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED) |
| Follow-up | 12 weeks |
| Comparator | Pill placebo with identical medication management schedule |
| Effect summary | improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED) |
| Effect modifiers | [{"modifier": "Primary anxiety diagnosis (SAD, SP, GAD)", "interaction_p": "p>.05", "direction": "null", "stratum_details": "", "plain_language": "Sertraline worked regardless of which anxiety disorder was primary.", "annotation_notes": ""}, {"modifier": "Youth age", "interaction_p": "p>.05", "direction": "null", "stratum_details": "", "plain_language": "Sertraline worked similarly for younger children and adolescents.", "annotation_notes": ""}] |
Connected entities
Interventions
Conditions
Outcomes
Populations
Source
PMC6425733
Secondary Outcomes From the Child/Adolescent Anxiety Multimodal Study: Implications for Clinical Practice